Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Elsevier uses machine learning to benefit pharmacovigilance
Posted on November 7th, 2019 by Xuanyan Xu in Pharmacovigilance
Monitoring the scientific literature for adverse drug reactions (ADRs) is critical to maintaining drug safety, and there is no room for error. As regulations tighten, pharmacovigilance teams are seeking better strategies and methods for ensuring that all ADRs are identified in the most effective and efficient way possible.
(more…)Three factors to unlock the value of AI for life sciences
Posted on May 1st, 2019 by Christy J. Wilson in Pharma R&D
Artificial Intelligence (AI) has been at the top of many boardroom agendas for the last several years, as execs try to integrate the technology. Recent RELX research found that, across all industries, 88 percent of senior executives believe AI will help their businesses be more competitive. In the life sciences, AI has the potential to scale the benefits of precision medicine or automated disease prediction to more patients across the world, and could generate more than $150 billion in savings for the healthcare industry by 2025.
(more…)Machine Learning Is Accelerating the Pace of Drug Development, But Good Data is Key
Posted on April 19th, 2019 by Frederik van den Broek in Pharma R&D
Artificial Intelligence, Machine Learning and Deep Learning are on the tip of everyone’s tongues when it comes to acceleration of the pace of discovery The Pharma R&D market is a perfect exemplification of this phenomenon. Medical advancements enabled by such technologies have proven to significantly accelerate discovery processes, saving valuable time and money required for the development of life changing solutions. That being said, there is the reality that human beings with a passion and talent for feeding such mechanisms still and likely always will provide invaluable inputs. In short, we are not to be replaced by these advancements; rather the changes are indicative of a new era of advancement defined by “partnerships” between humans and machines.
(more…)When research gives you lemons – turning R&D failures into opportunities and success
Posted on February 19th, 2019 by Veaceslav Mamaliga in Pharma R&D
As highlighted in my colleague, Nicki Catchpole’s last post on accidental drug discovery, 90 Years of Penicillin, the landscape of R&D is littered with ‘failures’ that turned out to be vital innovations. Pharmaceutical R&D is no exception.
(more…)
